Abstract:Objective: SGLT2 inhibitors belong to a new category of oral antidiabetic medications that decrease blood glucose by obstructing glucose reabsorption in the proximal tubule (PCT), resulting in elevated urinary levels of sodium and glucose. The 2023 ESC guidelines for acute and chronic heart failure encourage the usage of SGLT2 inhibitors in patients with HFmrEF and HFpEF to lower the danger of hospitalization or cardiovascular mortality in heart failure patients. Cognitive decline is a significant issue for heart failure patients. This narrative review's objective is to examine the impact of SGLT2i on cognitive dysfunction associated with heart failure and foster further research, predominantly in the form of large-scale clinical trials. Design and method: An exhaustive literature search was executed on PubMed to analyze the fundamental mechanisms of SHLT2 inhibitors on cognitive impairment in heart failure patients, related clinical evaluations, the consequences of cardiac dysfunction on cognitive function, and possible underlying mechanisms. Results: The published literature substantiates the argument that cognitive impairment is provoked by cardiac dysfunction. Current research suggests that cognitive dysfunction in patients with heart failure results from inadequate cerebral perfusion, the Locus coeruleus noradrenergic system, chronic inflammation, mitochondrial dysfunction, and microRNA-1. Furthermore, numerous randomized controlled trials have confirmed that SGLT2 inhibitors, with or without diabetes mellitus, enhance cardio-renal outcomes in patients. SGLT2 proteins are present in the central nervous system (CNS). SGLT2 inhibitors reduce oxidative stress, inflammation, and endothelial cell proliferation, as well as improve brain mitochondrial function, synaptic plasticity, acetylcholinesterase activity, amyloid plaques, and modulation of the mTOR pathway. They also attenuate brain injury and cognitive decline. There are additional clinical studies that demonstrate the reduction in the risk of cerebrovascular events and dementia through SGLT2i treatment. Conclusions: To summarize, all existing studies establish the direct and indirect neuroprotective effects of SGLT2i. Nevertheless, there is limited clinical research on using SGLT2i for the treatment of cognitive dysfunction related to heart failure. Further clinical experiments are required to determine the effectiveness of SGLT2i treatment in improving cognitive dysfunction associated with heart failure.

SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system

The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients

IMPROVEMENT OF COGNITIVE FUNCTION IN HEART FAILURE PATIENTS BY SGLT2 INHIBITORS—CLINICAL ADVANCES, MECHANISMS, AND FUTURE PERSPECTIVES

Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline

Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control

Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

Dapagliflozin improves diabetic cognitive impairment via indirectly modulating the mitochondria homeostasis of hippocampus in diabetic mice

Potential roles of Glucagon-like peptide-1 and its analogues in cognitive impairment associated with type 2 diabetes mellitus

Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection

The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD

Impact of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors on Atherosclerosis: from Pharmacology to Pre-Clinical and Clinical Therapeutics

Sodium–glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes

Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism

Applications of SGLT2 inhibitors beyond glycaemic control

Abstract 50: Sodium-Glucose Cotransporter 2 Inhibitors Use in Diabetic Patients With Acute Ischemic Stroke is Linked to Favorable Neurological Outcomes

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study with Competing Risk Analysis

894-P: Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Dementia in People with Type 2 Diabetes—A Population-Based Cohort Study

SGLT2 Inhibitors: a New Therapy for Diabetes

Research progress on the effects of SGLT2 inhibitors on multiple metabolic disorders in metabolic syndrome

Neuroprotective Effects of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors (Gliflozins) on Diabetes-Induced Neurodegeneration and Neurotoxicity: A Graphical Review